GENMAB A/S
GMABNasdaq
$28.72
↓ -0.9%Jul 17 close · end-of-day
Price
1Y↑ +31.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.
- CEO
- Jan G. J. van de Winkel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,660
- Website
- genmab.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | Buy | 75,867,199 | $97.00 | $7.4B | filing |
| 2025-12-29 | GENMAB A/S | Buy | 1,052,806 | $97.00 | $102.1M | filing |
| 2025-12-26 | GENMAB A/S | Buy | 142,610 | $97.00 | $13.8M | filing |
| 2025-12-26 | GENMAB A/S | Buy | 2,978 | $97.00 | $288,866.00 | filing |
| 2025-12-24 | GENMAB A/S | Buy | 96,082 | $97.00 | $9.3M | filing |
| 2025-12-23 | GENMAB A/S | Buy | 561,042 | $97.00 | $54.4M | filing |
| 2025-12-22 | GENMAB A/S | Buy | 15,710 | $97.00 | $1.5M | filing |
| 2025-12-19 | GENMAB A/S | Buy | 66,264 | $97.00 | $6.4M | filing |
| 2025-12-18 | GENMAB A/S | Buy | 212,177 | $97.00 | $20.6M | filing |
| 2025-12-17 | GENMAB A/S | Buy | 150,795 | $97.00 | $14.6M | filing |
| 2025-12-16 | GENMAB A/S | Buy | 120,752 | $97.00 | $11.7M | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.